- Associated Press - Monday, August 6, 2018

ST. LOUIS (AP) - Pharmaceutical manufacturer Mallinckrodt has announced plans to spend up to $10 million over five years to fund research at the Washington University School of Medicine in St. Louis.

The St. Louis Post-Dispatch reports that the partnership will fund projects that have a focus on rare diseases. Mallinckrodt’s Chief Scientific Officer, Dr. Steven Romano, says many underserved patients have “few, if any, therapeutic options.”

Mallinckrodt is based in the United Kingdom, and its U.S. headquarters are in the St. Louis suburb of Hazelwood.

Sign up for Daily Newsletters

Copyright © 2019 The Washington Times, LLC.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.

 

Click to Read More and View Comments

Click to Hide